VCNX

SEC source: 0001062993-24-019266 · form4.xml · derivative · entry 5

FRIEDBERG ALBERT · CIK 0001268239 · Director · 10% owner

FCMI Parent Co. · CIK 0001678258 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By FCMI Parent Co.

Disclosed balance after: 584,646

Underlying: Common Stock · 584,646 shares

Expires not disclosed

F4 · derivative.exercise_date: These pre-funded warrants are currently exercisable, subject to a 39.99% beneficial ownership limitation on the reporting persons, at an initial exercise price of $0.0001 and will expire on the date they are exercised in full.

F4 · derivative.expiration_date: These pre-funded warrants are currently exercisable, subject to a 39.99% beneficial ownership limitation on the reporting persons, at an initial exercise price of $0.0001 and will expire on the date they are exercised in full.

F3 · ownership.nature: Mr. Friedberg is the majority owner, a director and the president of FCMI Parent Co. ("FCMI") and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001062993-24-019266 · form4.xml · nonDerivative · entry 4

FRIEDBERG ALBERT · CIK 0001268239 · Director · 10% owner

FCMI Parent Co. · CIK 0001678258 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By FCMI Parent Co.

Disclosed balance after: 1,051,389

F3 · ownership.nature: Mr. Friedberg is the majority owner, a director and the president of FCMI Parent Co. ("FCMI") and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001062993-24-019265 · form4.xml · nonDerivative · entry 4

Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner

Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Vaccinex (Rochester), L.L.C.

Disclosed balance after: 297,941

F2 · ownership.nature: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001062993-24-016838 · form4.xml · derivative · entry 8

FRIEDBERG ALBERT · CIK 0001268239 · Director · 10% owner

FCMI Parent Co. · CIK 0001678258 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By FCMI Parent Co.

Disclosed balance after: 653,210

Underlying: Common Stock · 653,210 shares

Expires 2029-09-18

F3 · ownership.nature: Mr. Friedberg is the majority owner, a director and the president of FCMI Parent Co. ("FCMI") and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001062993-24-016838 · form4.xml · derivative · entry 7

FRIEDBERG ALBERT · CIK 0001268239 · Director · 10% owner

FCMI Parent Co. · CIK 0001678258 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By FCMI Parent Co.

Disclosed balance after: 92,504

Underlying: Common Stock · 25,723 shares

Expires 2029-02-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: This warrant was originally reported on Form 4 with an exercise price of $14.00. Pursuant to the Warrant Inducement Agreement, the exercise price of this warrant was adjusted to $5.636. FCMI partially exercised this warrant for 25,723 shares at an exercise price of $5.636 per share and pre-funded the remaining 92,504 shares at a price of $5.635. The exercise price for the remaining 92,504 shares underlying this warrant was subsequently adjusted to $0.001.

F3 · ownership.nature: Mr. Friedberg is the majority owner, a director and the president of FCMI Parent Co. ("FCMI") and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001062993-24-016838 · form4.xml · derivative · entry 6

FRIEDBERG ALBERT · CIK 0001268239 · Director · 10% owner

FCMI Parent Co. · CIK 0001678258 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By FCMI Parent Co.

Disclosed balance after: 0

Underlying: Common Stock · 214,286 shares

Expires 2028-10-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: This warrant was originally reported on Form 4 with an exercise price of $14.00. Pursuant to a warrant inducement agreement by and between the issuer and FCMI dated September 17, 2024 (the "Warrant Inducement Agreement"), the exercise price of this warrant was adjusted to $5.636.

F3 · ownership.nature: Mr. Friedberg is the majority owner, a director and the president of FCMI Parent Co. ("FCMI") and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001062993-24-016838 · form4.xml · nonDerivative · entry 5

FRIEDBERG ALBERT · CIK 0001268239 · Director · 10% owner

FCMI Parent Co. · CIK 0001678258 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By FCMI Parent Co.

Disclosed balance after: 1,020,633

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: This warrant was originally reported on Form 4 with an exercise price of $14.00. Pursuant to the Warrant Inducement Agreement, the exercise price of this warrant was adjusted to $5.636. FCMI partially exercised this warrant for 25,723 shares at an exercise price of $5.636 per share and pre-funded the remaining 92,504 shares at a price of $5.635. The exercise price for the remaining 92,504 shares underlying this warrant was subsequently adjusted to $0.001.

F3 · ownership.nature: Mr. Friedberg is the majority owner, a director and the president of FCMI Parent Co. ("FCMI") and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001062993-24-016838 · form4.xml · nonDerivative · entry 4

FRIEDBERG ALBERT · CIK 0001268239 · Director · 10% owner

FCMI Parent Co. · CIK 0001678258 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By FCMI Parent Co.

Disclosed balance after: 994,910

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: This warrant was originally reported on Form 4 with an exercise price of $14.00. Pursuant to a warrant inducement agreement by and between the issuer and FCMI dated September 17, 2024 (the "Warrant Inducement Agreement"), the exercise price of this warrant was adjusted to $5.636.

F3 · ownership.nature: Mr. Friedberg is the majority owner, a director and the president of FCMI Parent Co. ("FCMI") and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001062993-24-016842 · form4.xml · derivative · entry 12

Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner

Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Vaccinex (Rochester), L.L.C.

Disclosed balance after: 170,475

Underlying: Common Stock · 170,475 shares

Expires 2029-09-18

F2 · ownership.nature: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001062993-24-016842 · form4.xml · derivative · entry 11

Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner

Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Vaccinex (Rochester), L.L.C.

Disclosed balance after: 0

Underlying: Common Stock · 35,715 shares

Expires 2028-10-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: This warrant was originally reported on Form 4 with an exercise price of $14.00. Pursuant to the Warrant Inducement Agreement, the exercise price of this warrant was adjusted to $5.636.

F2 · ownership.nature: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001062993-24-016842 · form4.xml · derivative · entry 10

Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner

Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Vaccinex (Rochester), L.L.C.

Disclosed balance after: 0

Underlying: Common Stock · 9,768 shares

Expires 2028-11-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: This warrant was originally reported on Form 4 with an exercise price of $32.76. Pursuant to the Warrant Inducement Agreement, the exercise price of this warrant was adjusted to $5.636.

F2 · ownership.nature: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001062993-24-016842 · form4.xml · derivative · entry 9

Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner

Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Vaccinex (Rochester), L.L.C.

Disclosed balance after: 0

Underlying: Common Stock · 29,557 shares

Expires 2029-02-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: This warrant was originally reported on Form 4 with an exercise price of $14.00. Pursuant to the Warrant Inducement Agreement, the exercise price of this warrant was adjusted to $5.636.

F2 · ownership.nature: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001062993-24-016842 · form4.xml · derivative · entry 8

Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner

Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Vaccinex (Rochester), L.L.C.

Disclosed balance after: 0

Underlying: Common Stock · 38,610 shares

Expires 2029-03-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: This warrant was originally reported on Form 4 with an exercise price of $7.64. Pursuant to a warrant inducement agreement by and between the issuer and Vaccinex (Rochester) L.L.C. dated September 17, 2024 (the "Warrant Inducement Agreement"), the exercise price of this warrant was adjusted to $5.636.

F2 · ownership.nature: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001062993-24-016842 · form4.xml · nonDerivative · entry 7

Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner

Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Vaccinex (Rochester), L.L.C.

Disclosed balance after: 251,788

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: This warrant was originally reported on Form 4 with an exercise price of $14.00. Pursuant to the Warrant Inducement Agreement, the exercise price of this warrant was adjusted to $5.636.

F2 · ownership.nature: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001062993-24-016842 · form4.xml · nonDerivative · entry 6

Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner

Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Vaccinex (Rochester), L.L.C.

Disclosed balance after: 216,073

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: This warrant was originally reported on Form 4 with an exercise price of $32.76. Pursuant to the Warrant Inducement Agreement, the exercise price of this warrant was adjusted to $5.636.

F2 · ownership.nature: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001062993-24-016842 · form4.xml · nonDerivative · entry 5

Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner

Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Vaccinex (Rochester), L.L.C.

Disclosed balance after: 206,305

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: This warrant was originally reported on Form 4 with an exercise price of $14.00. Pursuant to the Warrant Inducement Agreement, the exercise price of this warrant was adjusted to $5.636.

F2 · ownership.nature: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001062993-24-016842 · form4.xml · nonDerivative · entry 4

Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner

Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Vaccinex (Rochester), L.L.C.

Disclosed balance after: 176,748

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: This warrant was originally reported on Form 4 with an exercise price of $7.64. Pursuant to a warrant inducement agreement by and between the issuer and Vaccinex (Rochester) L.L.C. dated September 17, 2024 (the "Warrant Inducement Agreement"), the exercise price of this warrant was adjusted to $5.636.

F2 · ownership.nature: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001062993-24-014976 · form4.xml · nonDerivative · entry 4

FRIEDBERG ALBERT · CIK 0001268239 · Director · 10% owner

FCMI Parent Co. · CIK 0001678258 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By FCMI Parent Co.

Disclosed balance after: 780,624

F3 · ownership.nature: Mr. Friedberg is the majority owner, a director and the president of FCMI Parent Co. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001062993-24-014577 · form4.xml · nonDerivative · entry 5

FRIEDBERG ALBERT · CIK 0001268239 · Director · 10% owner

FCMI Parent Co. · CIK 0001678258 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By FCMI Parent Co.

Disclosed balance after: 780,524

F3 · ownership.nature: Mr. Friedberg is the majority owner, a director and the president of FCMI Parent Co. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001062993-24-014577 · form4.xml · nonDerivative · entry 4

FRIEDBERG ALBERT · CIK 0001268239 · Director · 10% owner

FCMI Parent Co. · CIK 0001678258 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By FCMI Parent Co.

Disclosed balance after: 777,771

F3 · ownership.nature: Mr. Friedberg is the majority owner, a director and the president of FCMI Parent Co. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001062993-24-014364 · form4.xml · nonDerivative · entry 4

FRIEDBERG ALBERT · CIK 0001268239 · Director · 10% owner

FCMI Parent Co. · CIK 0001678258 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By FCMI Parent Co.

Disclosed balance after: 774,118

F3 · ownership.nature: Mr. Friedberg is the majority owner, a director and the president of FCMI Parent Co. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001062993-24-014289 · form4.xml · nonDerivative · entry 6

FRIEDBERG ALBERT · CIK 0001268239 · Director · 10% owner

FCMI Parent Co. · CIK 0001678258 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By FCMI Parent Co.

Disclosed balance after: 762,415

F6 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.18 to $7.40, inclusive. The reporting persons undertake to provide Vaccinex, Inc., any security holder of Vaccinex, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F3 · ownership.nature: Mr. Friedberg is the majority owner, a director and the president of FCMI Parent Co. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001062993-24-014289 · form4.xml · nonDerivative · entry 5

FRIEDBERG ALBERT · CIK 0001268239 · Director · 10% owner

FCMI Parent Co. · CIK 0001678258 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By FCMI Parent Co.

Disclosed balance after: 746,287

F5 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.11 to $7.06, inclusive. The reporting persons undertake to provide Vaccinex, Inc., any security holder of Vaccinex, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F3 · ownership.nature: Mr. Friedberg is the majority owner, a director and the president of FCMI Parent Co. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001062993-24-014289 · form4.xml · nonDerivative · entry 4

FRIEDBERG ALBERT · CIK 0001268239 · Director · 10% owner

FCMI Parent Co. · CIK 0001678258 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By FCMI Parent Co.

Disclosed balance after: 663,044

F4 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.10 to $6.10, inclusive. The reporting persons undertake to provide Vaccinex, Inc., any security holder of Vaccinex, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F3 · ownership.nature: Mr. Friedberg is the majority owner, a director and the president of FCMI Parent Co. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001062993-24-011556 · form4.xml · nonDerivative · entry 5

FRIEDBERG ALBERT · CIK 0001268239 · Director · 10% owner

FCMI Parent Co. · CIK 0001678258 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By FCMI Parent Co.

Disclosed balance after: 562,415

F4 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.17 to $5.20. The reporting persons undertake to provide Vaccinex, Inc., any security holder of Vaccinex, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F3 · ownership.nature: Mr. Friedberg is the majority owner, a director and the president of FCMI Parent Co. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001062993-24-011556 · form4.xml · nonDerivative · entry 4

FRIEDBERG ALBERT · CIK 0001268239 · Director · 10% owner

FCMI Parent Co. · CIK 0001678258 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By FCMI Parent Co.

Disclosed balance after: 561,554

F3 · ownership.nature: Mr. Friedberg is the majority owner, a director and the president of FCMI Parent Co. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001062993-24-010182 · form4.xml · derivative · entry 7

MANIAN BALA S · CIK 0000941871 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,108

Underlying: Common Stock · 10,108 shares

Expires not disclosed

F7 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 10, 2034 or five years following retirement or cessation of services, whichever occurs first.

SEC source: 0001062993-24-010182 · form4.xml · derivative · entry 6

MANIAN BALA S · CIK 0000941871 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,685

Underlying: Common Stock · 2,685 shares

Expires 2034-05-10

F6 · price: Pursuant to the Issuer's Director Compensation Plan, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $10,625 for retainer and meeting fees during the first quarter of 2024. The number of options was calculated in accordance with the Black-Scholes valuation model and all such options are immediately exercisable.

SEC source: 0001062993-24-010181 · form4.xml · derivative · entry 5

Stecyk Chrystyna Bedrij · CIK 0001811625 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,108

Underlying: Common Stock · 10,108 shares

Expires not disclosed

F5 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 10, 2034 or five years following retirement or cessation of services, whichever occurs first.

SEC source: 0001062993-24-010179 · form4.xml · derivative · entry 29

Frieberg Jacob B. · CIK 0001748346 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,108

Underlying: Common Stock · 10,108 shares

Expires not disclosed

F10 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 10, 2034 or five years following retirement or cessation of services, whichever occurs first.

SEC source: 0001062993-24-010179 · form4.xml · derivative · entry 28

Frieberg Jacob B. · CIK 0001748346 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,211

Underlying: Common Stock · 2,211 shares

Expires 2034-05-10

F9 · price: Pursuant to the Issuer's Director Compensation Plan, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the first quarter of 2024. The number of options was calculated in accordance with the Black-Scholes valuation model and all such options are immediately exercisable.

SEC source: 0001062993-24-010184 · form4.xml · derivative · entry 7

Yanni Barbara · CIK 0001610561 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,108

Underlying: Common Stock · 10,108 shares

Expires not disclosed

F7 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 10, 2034 or five years following retirement or cessation of services, whichever occurs first.

SEC source: 0001062993-24-010183 · form4.xml · derivative · entry 12

Van Strydonck, Gerald E. · CIK 0001748247 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,108

Underlying: Common Stock · 10,108 shares

Expires not disclosed

F8 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 10, 2034 or five years following retirement or cessation of services, whichever occurs first.

SEC source: 0001062993-24-010183 · form4.xml · nonDerivative · entry 1

Van Strydonck, Gerald E. · CIK 0001748247 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 543

F1 · shares: Pursuant to the Issuer's Director Compensation Plan, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these restricted shares in lieu of $3,125 for retainer and meeting fees during the first quarter of 2024.

SEC source: 0001062993-24-008643 · form4.xml · nonDerivative · entry 4

FRIEDBERG ALBERT · CIK 0001268239 · Director · 10% owner

FCMI Parent Co. · CIK 0001678258 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By FCMI Parent Co.

Disclosed balance after: 560,597

F3 · ownership.nature: Mr. Friedberg is the majority owner, a director and the president of FCMI Parent Co. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001062993-24-007660 · form4.xml · derivative · entry 5

FRIEDBERG ALBERT · CIK 0001268239 · Director · 10% owner

FCMI Parent Co. · CIK 0001678258 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By FCMI Parent Co.

Disclosed balance after: 102,960

Underlying: Common Stock · 102,960 shares

Expires 2029-03-28

F3 · ownership.nature: Mr. Friedberg is the majority owner, a director and the president of FCMI Parent Co. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001062993-24-007660 · form4.xml · nonDerivative · entry 4

FRIEDBERG ALBERT · CIK 0001268239 · Director · 10% owner

FCMI Parent Co. · CIK 0001678258 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By FCMI Parent Co.

Disclosed balance after: 560,315

F3 · shares: Mr. Friedberg is the majority owner, a director and the president of FCMI Parent Co. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

F3 · balance_after: Mr. Friedberg is the majority owner, a director and the president of FCMI Parent Co. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

F3 · ownership.nature: Mr. Friedberg is the majority owner, a director and the president of FCMI Parent Co. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001062993-24-007661 · form4.xml · derivative · entry 5

Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner

Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Vaccinex (Rochester), L.L.C.

Disclosed balance after: 38,610

Underlying: Common Stock · 38,610 shares

Expires 2029-03-28

F2 · ownership.nature: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001062993-24-007661 · form4.xml · nonDerivative · entry 4

Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner

Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Vaccinex (Rochester), L.L.C.

Disclosed balance after: 138,138

F2 · shares: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

F2 · balance_after: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

F2 · ownership.nature: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001062993-24-010187 · form4a.xml · derivative · entry 1

Sanchez Jill · CIK 0002015024 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 805

Underlying: Common Stock · 805 shares

Expires 2034-03-21

F1 · derivative.exercise_price: Due to an administrative error, the original Form 4 mistakenly listed the transaction date as March 20, 2024. The transaction actually occurred on March 21, 2024. Accordingly, the exercise price of the stock option is $8.21 per share, as opposed to the exercise price of $8.32 that was listed in the original Form 4.

F1 · date: Due to an administrative error, the original Form 4 mistakenly listed the transaction date as March 20, 2024. The transaction actually occurred on March 21, 2024. Accordingly, the exercise price of the stock option is $8.21 per share, as opposed to the exercise price of $8.32 that was listed in the original Form 4.

F2 · derivative.exercise_date: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 21, 2024 grant date.

SEC source: 0001062993-24-010186 · form4a.xml · derivative · entry 1

Evans Elizabeth E. · CIK 0001863447 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,341

Underlying: Common Stock · 1,341 shares

Expires 2034-03-21

F1 · derivative.exercise_price: Due to an administrative error, the original Form 4 mistakenly listed the transaction date as March 20, 2024. The transaction actually occurred on March 21, 2024. Accordingly, the exercise price of the stock option is $8.21 per share, as opposed to the exercise price of $8.32 that was listed in the original Form 4.

F1 · date: Due to an administrative error, the original Form 4 mistakenly listed the transaction date as March 20, 2024. The transaction actually occurred on March 21, 2024. Accordingly, the exercise price of the stock option is $8.21 per share, as opposed to the exercise price of $8.32 that was listed in the original Form 4.

F2 · derivative.exercise_date: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 21, 2024 grant date.

SEC source: 0001062993-24-010189 · form4a.xml · derivative · entry 1

Smith Ernest S. · CIK 0001747769 · SVP, Research & CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,341

Underlying: Common Stock · 1,341 shares

Expires 2034-03-21

F1 · derivative.exercise_price: Due to an administrative error, the original Form 4 mistakenly listed the transaction date as March 20, 2024. The transaction actually occurred on March 21, 2024. Accordingly, the exercise price of the stock option is $8.21 per share, as opposed to the exercise price of $8.32 that was listed in the original Form 4.

F1 · date: Due to an administrative error, the original Form 4 mistakenly listed the transaction date as March 20, 2024. The transaction actually occurred on March 21, 2024. Accordingly, the exercise price of the stock option is $8.21 per share, as opposed to the exercise price of $8.32 that was listed in the original Form 4.

F2 · derivative.exercise_date: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 21, 2024 grant date.

SEC source: 0001062993-24-010185 · form4a.xml · derivative · entry 1

Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,877

Underlying: Common Stock · 1,877 shares

Expires 2034-03-21

F1 · derivative.exercise_price: Due to an administrative error, the original Form 4 mistakenly listed the transaction date as March 20, 2024. The transaction actually occurred on March 21, 2024. Accordingly, the exercise price of the stock option is $8.21 per share, as opposed to the exercise price of $9.15 that was listed in the original Form 4.

F1 · date: Due to an administrative error, the original Form 4 mistakenly listed the transaction date as March 20, 2024. The transaction actually occurred on March 21, 2024. Accordingly, the exercise price of the stock option is $8.21 per share, as opposed to the exercise price of $9.15 that was listed in the original Form 4.

F2 · derivative.exercise_date: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 21, 2024 grant date.

F3 · derivative.expiration_date: Due to an administrative error, the original Form 4 mistakenly listed the stock option expiration date as March 20, 2029. The expiration date is actually March 21, 2034.

SEC source: 0001062993-24-006958 · form4.xml · derivative · entry 7

Sanchez Jill · CIK 0002015024 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 805

Underlying: Common Stock · 805 shares

Expires 2034-03-20

F6 · derivative.exercise_date: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 30, 2024 grant date.

SEC source: 0001062993-24-006960 · form4.xml · derivative · entry 9

Evans Elizabeth E. · CIK 0001863447 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,341

Underlying: Common Stock · 1,341 shares

Expires 2034-03-20

F6 · derivative.exercise_date: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 20, 2024 grant date.

SEC source: 0001062993-24-006959 · form4.xml · derivative · entry 9

Smith Ernest S. · CIK 0001747769 · SVP, Research & CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,341

Underlying: Common Stock · 1,341 shares

Expires 2034-03-20

F5 · derivative.exercise_date: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 20, 2024 grant date.

SEC source: 0001062993-24-006957 · form4.xml · derivative · entry 15

Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,877

Underlying: Common Stock · 1,877 shares

Expires 2029-03-20

F7 · derivative.exercise_date: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 20, 2024 grant date.

SEC source: 0001062993-24-002769 · form4.xml · derivative · entry 5

FRIEDBERG ALBERT · CIK 0001268239 · Director · 10% owner

FCMI Parent Co. · CIK 0001678258 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By FCMI Parent Co.

Disclosed balance after: 1,655,172

Underlying: Common Stock · 1,655,172 shares

Expires 2029-02-08

F3 · ownership.nature: Mr. Friedberg is the majority owner, a director and the president of FCMI Parent Co. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001062993-24-002769 · form4.xml · nonDerivative · entry 4

FRIEDBERG ALBERT · CIK 0001268239 · Director · 10% owner

FCMI Parent Co. · CIK 0001678258 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By FCMI Parent Co.

Disclosed balance after: 6,402,966

F3 · shares: Mr. Friedberg is the majority owner, a director and the president of FCMI Parent Co. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

F3 · balance_after: Mr. Friedberg is the majority owner, a director and the president of FCMI Parent Co. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

F3 · ownership.nature: Mr. Friedberg is the majority owner, a director and the president of FCMI Parent Co. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001062993-24-002770 · form4.xml · derivative · entry 5

Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner

Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Vaccinex (Rochester), L.L.C.

Disclosed balance after: 413,793

Underlying: Common Stock · 413,793 shares

Expires 2029-02-08

F2 · ownership.nature: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.